Psychedelic Medicine News Articles

Excerpts of key news articles on

Below are key excerpts of inspiring news articles on psychedelic medicine from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

Note: Explore our full index to revealing excerpts of key major media news articles on dozens of engaging topics. And read excerpts from 20 of the most revealing news articles ever published.

For Jon Lubecky, the scars on his wrists are a reminder of the years he spent in mental purgatory. He returned from an Army deployment in Iraq a broken man. He got every treatment offered by Veterans Affairs for post-traumatic stress disorder. But they didn’t stop him from trying to kill himself - five times. Finally, he signed up for an experimental therapy and was given a little green capsule. The anguish stopped. Inside that pill was the compound MDMA, better known ... as ecstasy. That street drug is emerging as the most promising tool in years for the military’s escalating PTSD epidemic. The MDMA program was created by a small group of psychedelic researchers who had toiled for years in the face of ridicule, funding shortages and skepticism. But the results have been so positive that this month the Food and Drug Administration deemed it a “breakthrough therapy” - setting it on a fast track for review and potential approval. Only two drugs are approved for treating PTSD: Zoloft and Paxil. Both have proved largely ineffective. By giving doses of MDMA at the beginning of three, eight-hour therapy sessions, researchers say they have helped chronic PTSD patients process and move past their traumas. In clinical trials with 107 patients closely monitored by the FDA, 61 percent reported major reductions in symptoms - to the point where they no longer fit the criteria for PTSD. Follow-up studies a year later found 67 percent no longer had PTSD.

Note: Read more about how MDMA has been found effective for treating PTSD in a therapeutic context. Articles like this suggest that the healing potentials of mind-altering drugs are gaining mainstream scientific credibility.

As eight states plus the District of Columbia have moved to fully legalize recreational marijuana, debates on the merits of legalization have focused on the effects of marijuana use on individuals and society. The National Academies of Sciences, Medicine and Engineering have brought a great deal of clarity to the situation with an encyclopedic report summarizing pretty much everything researchers know (and don't know) about the health effects of marijuana use. For the 395-page report, a team of dozens of drug policy experts at some of the nation's most prestigious universities analyzed 24,000 scientific papers to arrive at more than 100 conclusions regarding the effects of marijuana use. The committee found strong evidence showing marijuana is effective at treating chronic pain in adults. Given the current public health crisis involving tens of thousands of deaths annually because of painkiller overdoses, this is a potentially significant finding. The report also turned up strong evidence that marijuana is effective at treating nausea and vomiting, [as well as] muscle spasticity. The literature shows limited evidence that marijuana use is linked to the use of other substances. The report does not address the implications of these findings for current legalization debates. The researchers do, however, state emphatically that the current designation of marijuana as a Schedule 1 controlled substance ... is one of the chief barriers to conducting more badly needed research.

Note: Big Pharma has been caught systematically bribing doctors to over-prescribe deadly painkillers, and an ex-DEA official has publicly accused Congress of helping drug makers avoid responsibility for their role in the US opioid epidemic. Meanwhile, more people are arrested in the US for marijuana use than for all violent crimes combined. For more along these lines, see concise summaries of deeply revealing news articles on government corruption and health.

Jackson Leyden had always been a healthy kid. But in 2011, a few months after his eighth birthday, he began having seizures several times a day. His parents took him to more than 20 doctors. He tried more than a dozen medications. Nothing worked. Two years ago, the Leydens ... decided to see whether marijuana might help. “Within a few days, he was having hardly any seizures,” says his mother, Lisa. “I was shocked.” Over the next few months, he stopped taking other medications. Not only did the medicine help, it did so without making him high. The strain of marijuana that Jackson takes is unusual: It contains high levels of cannabidiol, or CBD, one of the two main molecules in marijuana; the other is tetrahydrocannabinol, or THC. While THC is famously mind-altering, CBD is not. Over decades, researchers have found that THC may help treat pain, nausea, loss of appetite and other problems, while CBD was thought to be biologically inactive. But in the past 10 years ... dozens of studies have found evidence that the compound can treat epilepsy as well as a range of other illnesses, including anxiety, schizophrenia, heart disease and cancer. Now 13, Jackson ... continues to use marijuana every day. He still has seizures, but they are less severe and they occur once every week or two, down from around 200 a month before he started using cannabis. Although it doesn’t make users high, CBD ... is classified by the federal government as a Schedule 1 drug [with] no accepted medical use.

Note: While more people are arrested in the US for marijuana use than for all violent crimes combined and the US federal government continues to regard non-psychoactive CBD as a dangerous drug, the UK government recently announced it will regulate CBD as medicine. For more along these lines, see concise summaries of deeply revealing health news articles from reliable major media sources.

A group of 22 medical experts convened by Johns Hopkins University and The Lancet have called today for the decriminalization of all nonviolent drug use and possession. The experts further encourage countries and U.S. states to "move gradually toward regulated drug markets and apply the scientific method to their assessment." Their report comes ahead of a special UN General Assembly Session on drugs to be held next month. In a lengthy review of the state of global drug policy, the Hopkins-Lancet experts conclude that the prohibitionist anti-drug policies of the past 50 years "directly and indirectly contribute to lethal violence, disease, discrimination, forced displacement, injustice and the undermining of people’s right to health. "The goal of prohibiting all use, possession, production and trafficking of illicit drugs is the basis of many of our national drug laws, but these policies are based on ideas about drug use and drug dependence that are not scientifically grounded," said Commissioner Dr. Chris Beyrer. "The idea that all drug use is necessarily 'abuse' means that immediate and complete abstinence has been seen as the only acceptable approach," commissioner Adeeba Kamarulzaman ... said. But, she added, "continued criminalization of drug use fuels HIV, hepatitis C and tuberculosis transmission within prisons and the community at large. There is another way. Programmes and policies aimed at reducing harm should be central to future drug policies."

Note: While the war on drugs has been called a "trillion dollar failure", and the healing potentials of mind altering drugs are starting to be investigated more openly, there remains powerful evidence that the CIA and US military are directly involved in the drug trade.

In the 1950s through the early ’70s, research began to show that psychedelics like LSD and psilocybin, the active ingredient in magic mushrooms, could be quite effective at treating mental health disorders like addiction. Then ... the so-called “war on drugs” began. For nearly a generation, science on these substances shut down. But that’s changing. In the past 20 years or so, a small amount of research has once again begun to focus on these chemicals, showing that they have promise for treating a range of conditions, from addiction to depression and anxiety, says Evan Wood, a psychiatric researcher at the University of British Columbia. In 2006, researchers at the University of Arizona published a study showing obsessive-compulsive patients who ingested psilocybin had immediate and lasting reductions in problematic symptoms. The same year, Johns Hopkins University physician and researcher Roland Griffiths showed that in healthy volunteers, psilocybin produced lasting benefits like improved mood and peacefulness six months after ingestion. Similar work has shown psilocybin can help treat anxiety associated with cancer, at UCLA and New York University. And a study in late 2014 found that LSD permanently reduced anxiety in a small number of patients. Wood says he’s most excited about research into using psychedelics to treat addiction. He published a review on September 8 in the Canadian Medical Association Journal covering recent work in this field.

Note: For more about the therapeutic uses of psychedelic drugs, see these concise summaries of deeply revealing news articles from reliable sources.

Over the last year, I [CNN Chief Medical Correspondent Dr. Sanjay Gupta] have been working on a new documentary called "Weed." The title "Weed" may sound cavalier, but the content is not. I traveled around the world to interview medical leaders, experts, growers and patients. I spoke candidly to them, asking tough questions. What I found was stunning. Long before I began this project, I had steadily reviewed the scientific literature on medical marijuana from the United States and thought it was fairly unimpressive. Reading these papers five years ago, it was hard to make a case for medicinal marijuana. I even wrote about this in a TIME magazine article, back in 2009, titled "Why I would Vote No on Pot." Well, I am here to apologize. I apologize because I didn't look hard enough, until now. I didn't look far enough. I didn't review papers from smaller labs in other countries doing some remarkable research, and I was too dismissive of the loud chorus of legitimate patients whose symptoms improved on cannabis. I mistakenly believed the Drug Enforcement Agency listed marijuana as a schedule 1 substance because of sound scientific proof. Surely, they must have quality reasoning as to why marijuana is in the category of the most dangerous drugs that have "no accepted medicinal use and a high potential for abuse." They didn't have the science to support that claim, and I now know that when it comes to marijuana neither of those things are true. It doesn't have a high potential for abuse, and there are very legitimate medical applications. In fact, sometimes marijuana is the only thing that works.

Note: This article was authored by CNN's Chief Medical Correspondent, Dr. Sanjay Gupta. For more on the proven benefits from many mind-altering drugs, see the deeply revealing reports from reliable major media sources available here.

The World Health Organization estimates that ... depression and anxiety rose by more than 25 percent in the first year of the COVID pandemic, adding to the nearly one billion people who were already living with a mental disorder. One of the principal ways mental health disorders are thought to manifest is through severed connections between neurons – the winding, spindly cells in our brain and throughout our body essential for interpreting info from the external environment. Certain antidepressant drugs seem to work by increasing serotonin levels, an important neurotransmitter that the brain uses to send signals between neurons. They can help regrow neuronal connections ... only the effect seems to be slower, less dramatic [and] can come with significant drawbacks. In contrast, psychedelics can promote this kind of regrowth in as little as 24 hours, often less. Many experts believe psychedelic drugs ... act like Miracle Grow for neurons, helping them flourish like a dense forest. Pretty much the only reason drugs have a psychoactive effect on us at all is because they closely resemble chemicals our body already produces. Most psychedelic drugs like LSD, DMT and psilocybin are structurally similar to serotonin, so they can act on serotonin receptors, but in a slightly different way. You can think of it like clumsily-made lockpicks that still work in a lock designed for a specific key. But even the slight differences can have profound effects, specifically, altered perception of time and space and intensified colors and sounds.

Note: Read more on the healing potentials of psychedelic medicine. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.

Oregon on Wednesday became the first state to legalize the active ingredient in so-called magic mushrooms on an election night that saw more states ease restrictions on recreational drugs across the country. Oregon's Measure 109 will give legal access to psilocybin, the main active ingredient in "magic mushrooms," for mental health treatment in supervised settings. While some cities have moved to legalize and regulate access to the drug, Oregon will become the first state in the country to legalize it on a statewide basis. Supporters of the measure point to the medical benefits of the drug, which has been shown in some studies to benefit trauma survivors. Through Measure 110, which has captured more than 58% of the vote so far, Oregon would also decriminalize the possession of small amounts of some hard drugs, including heroin and LSD. Instead of criminal prosecution, people in possession would face a $100 fine, which can be waived if the person agrees to pursue treatment, according to the measure. Ronan Levy, the cofounder of Field Trip Health, a Toronto-based company that provides psychedelic-enhanced psychotherapy, said the ballot wins are "fantastic news" for what he called the psychedelic renaissance. Research is mounting that indicates the benefits of using psychedelic drugs to enhance therapy, Levy said, adding that ... the drug alone isn't necessarily helpful; it needs to be taken under supervision of trained personnel.

Note: Recent studies suggest psilocybin can be used to treat addiction and anxiety. For more along these lines, see concise summaries of deeply revealing news articles on the healing potential of mind-altering drugs from reliable major media sources.

Daniel Carcillo wanted two things in life: to play hockey and to be a father. By 30, he was a two-time Stanley Cup winner. By age 31, he was suicidal. After seven diagnosed concussions, Carcillo tells CNN that he was suffering from "dementia-like" symptoms, along with depression, anxiety and headaches. Carcillo says he also suffered from insomnia and disrupted sleep. He spent over $500,000 on prescription medications and treatments at stroke rehabilitation centers, brain centers, and concussion centers, as well as holistic therapies. Then in a "last-ditch effort" to try and alleviate his symptoms, he says he took a dose of psilocybin – the main psychoactive ingredient in magic mushrooms – in Denver, which became the first US city to decriminalize hallucinogenic mushrooms. "And I woke up the next day and I describe it as feeling the way I should," said Carcillo. "I felt like, for the first time in a very, very long time, I had a zest for life. All I wanted to do was get on FaceTime and call my wife and call my kids and get back home." Carcillo isn't the only athlete – former or current – openly talking about using psychedelics to treat various conditions. In 2022, residents in Colorado joined Oregon in voting to legalize psilocybin. Small clinical trials have shown that one or two doses of psilocybin, given in a therapeutic setting, can make dramatic and long-lasting changes in people suffering from treatment-resistant major depressive disorder.

Note: Read more about the the healing potential of psychedelic medicine. Explore more positive stories like this in our comprehensive inspiring news articles archive focused on solutions and bridging divides.

Australia has become the first country to recognise psychedelics as medicines, after the Therapeutic Goods Administration took researchers by surprise and approved the psychedelic substances in magic mushrooms and MDMA for use by people with certain mental health conditions. MDMA and psilocybin, the active ingredient in magic mushrooms, will be considered schedule 8 drugs - meaning they're approved for controlled use when prescribed by a psychiatrist - from July this year after the TGA acknowledged there were few other options for patients with specific treatment-resistant mental illnesses. The changes will allow MDMA to be used to treat post-traumatic stress disorder, and psilocybin for treatment-resistant depression. They will still be considered prohibited substances ... for all other usages. "Prescribing will be limited to psychiatrists, given their specialised qualifications and expertise to diagnose and treat patients with serious mental health conditions," a TGA statement published on Friday said. Associate Professor David Caldicott, an emergency department doctor who appeared at the Royal Commission into Defence and Veteran Suicide ... was pleasantly surprised by Friday's decision. "The conditions for which these drugs might be used [post-traumatic stress disorder and treatment-resistant depression] are currently conditions for which you're basically destined to a lifetime of drug use. Whereas the MDMA particularly is used to facilitate psychotherapy, only for a few doses," [said Caldicott].

Note: For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.

Colorado is poised to become the second U.S. state to legalize medicinal psychedelics. Proposition 122, Access to Natural Psychedelic Substances, was supported by about 52% of the vote ... according to the Secretary of State's Office. The measure legalizes psilocybin and psilocin, two compounds found in "magic mushrooms," for use in therapeutic settings and paves the way for the establishment of "healing centers" where adults 21 years old and up can use the substances under the supervision of licensed professionals. Additionally, Proposition 122 decriminalizes the personal growing, use and sharing of psilocybin and psilocin, as well as ibogaine, mescaline and dimethyltryptamine, or DMT, for adults. Colorado follows Oregon, which legalized psilocybin in 2020. Natural Medicine Colorado lauded the results as a history-making win. "Colorado voters saw the benefit of regulated access to natural medicines, including psilocybin, so people with PTSD, terminal illness, depression, anxiety and other mental health issues can heal," said the measure's co-proponents, Kevin Matthews and Veronica Lightening Horse Perez, in a statement. Proposition 122 gives the Department of Regulatory Agencies (DORA) until January 2024 to develop licensing criteria for psychedelic treatment centers, facilitators, and ancillary businesses.

Note: For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.

Key Articles From Years Past

For most of his adult life, Aaron Presley, age 34, felt like a husk of a person, a piece of "garbage." Then, all at once, the soul-crushing, depressive fog started to lift, and the most meaningful experience of his life began. The turning point for Presley came as he lay on a psychiatrist's couch at Johns Hopkins University. He had consumed a large dose of psilocybin, the active ingredient in what's more commonly known as magic mushrooms, and entered a state that could best be described as lucid dreaming. Visions of family and childhood triggered overwhelming and long-lost feelings of love, he says. Presley was one of 24 volunteers taking part in a small study aimed at evaluating the effectiveness of a combination of psychotherapy and this powerful mind-altering drug to treat depression–an approach that, should it win approval, could be the biggest advance in mental health since Prozac in the 1990s. Depression ... affects 320 million people around the world. Roughly one-third of those who seek treatment won't respond to verbal or conventional drug therapies. Magic-mushroom therapy is offering some hope for these hopeless cases. In the Hopkins study, published last year in JAMA Psychiatry, the therapy was four times more effective than traditional antidepressants. Two-thirds of participants showed a more-than 50-percent reduction in depression symptoms after one week; a month later, more than half were considered in remission, meaning they no longer qualified as being depressed.

Note: Read more about the healing potentials of mind-altering drugs. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.

Gov. Kate Brown of Oregon announced the members of the state's newly formed Psilocybin Advisory Board this week. Oregon is about to become the first state in the country to try to build a support infrastructure through which psychedelic mushrooms can be woven into everyday life. This framework is different from what we've seen before: not legalization, not medicalization, but therapeutic use, in licensed facilities, under the guidance of professionals trained to guide psychedelic experiences. The ... pressing case for psilocybin comes from research out of Johns Hopkins, U.C.L.A., N.Y.U. and elsewhere that has shown it to be a potentially effective treatment for major depression, end-of-life anxiety and drug addiction. "One of the things I've come to is that addiction medicine in 2021 is in desperate need of transformative technologies," Todd Korthuis, a ... member of Oregon's Psilocybin Advisory Board, told me. Studies ... are "showing dramatic change in people's lives – that's what we need for cocaine use disorder, methamphetamine use disorder, even alcohol and tobacco." A recent study on major depressive disorder, published in JAMA Psychiatry, found more than half of the subjects in remission four weeks later, after just two treatments alongside psychotherapy. A study on tobacco addiction, out of Johns Hopkins, found two-thirds of the subjects who received psilocybin in combination with cognitive behavioral therapy abstinent a year later.

Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.

A group of Silicon Valley and Wall Street executives has raised $30 million to speed the development of a closely watched psychedelic-drug therapy. The Multidisciplinary Association for Psychedelic Studies, a nonprofit advocating for psychedelic research since the 1980s, is conducting its last phase of clinical trials to research the efficacy of using MDMA-assisted psychotherapy for post-traumatic stress disorder. PTSD afflicts about eight million adults a year. MDMA is more commonly known as the main component of Ecstasy. Armed with the new funding, MAPS is aiming to finish the trials and seek approval from the Food and Drug Administration to commercialize the MDMA-assisted psychotherapy as soon as 2022. In 2017, the FDA designated MDMA as a breakthrough therapy for PTSD, meaning it would expedite review of the drug. MAPS said a recent interim analysis of its Phase 3 clinical trials ... showed a very high likelihood the therapy will be effective for treating PTSD. In phase 2 clinical trials, individuals with post-traumatic stress disorder received psychotherapy, some with the psychedelic drug MDMA. More of those who received the drug no longer received a PTSD diagnosis in the months after treatment, compared with those who received a placebo. Business leaders said their donations came from a personal connection to mental-health conditions. Among them is billionaire Bob Parsons, founder of GoDaddy and ... a Marine Corps Vietnam War veteran, who said he has continued to battle PTSD.

Note: To read the entire article free of charge, see this webpage. Note that as big Pharma won't make big profits from these therapies, they are not funding any of the major studies, while the nonprofit MAPS has stepped in to make this happen. And not mentioned in this article is that the results of these studies has been dramatic, with over 2/3 of patients showing no signs of PTSD a year after treatment. For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.

Mr. McCourry, a former U.S. Marine, had been crippled by post-traumatic stress disorder ever since returning from Iraq in 2004. He could not sleep, pushed away friends and family and developed a drinking problem. The numbness he felt was broken only by bouts of rage and paranoia. He was contemplating suicide when his sister heard about a novel clinical trial using the psychedelic drug MDMA, paired with therapy, to treat PTSD. Desperate, he enrolled in 2012. PTSD is a major public health problem worldwide and is particularly associated with war. In the United States, an estimated 13 percent of combat veterans and up to 20 to 25 percent of those deployed to Iraq and Afghanistan are diagnosed with PTSD at some point in their lives, compared with seven percent of the general population. There is growing evidence that MDMA – the illegal drug known as Ecstasy or Molly – can significantly lessen or even eliminate symptoms of PTSD when the treatment is paired with talk therapy. Last year, scientists reported in Nature Medicine the most encouraging results to date. The 90 participants in the study had all suffered from severe PTSD for more than 14 years on average. Each received three therapy sessions with either MDMA or a placebo, spaced one month apart and overseen by a two-person therapist team. Two months after treatment, 67 percent of those who received MDMA no longer qualified for a PTSD diagnosis, compared with 32 percent who received the placebo. As in previous trials, MDMA caused no serious side effects.

Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.

Jose Martinez, a former Army gunner whose right arm and both legs were blown off by a roadside bomb in Afghanistan, has a new calling: He's become one of the most effective lobbyists in a campaign to legalize the therapeutic use of psychedelic drugs across the country. On a Zoom call ... with Connie Leyva, a Democratic legislator in California who has long opposed relaxing drug laws, Mr. Martinez told her how psilocybin, the psychoactive ingredient in "magic" mushrooms, had helped to finally quell the physical pain and suicidal thoughts that had tormented him. Ms. Leyva says she changed her mind even before the call ended, and she later voted yes on the bill, which is expected to become law early next year. In the two years since Oregon, Washington, D.C., and a half-dozen municipalities decriminalized psilocybin, vets have become leading advocates in the drive to legalize psychedelic medicine, which they credit with helping ease the post-traumatic stress, anxiety and depression that are often tied to their experiences in the military. The campaign has been propelled by the epidemic of suicides among veterans ... but also by the national reckoning over the mass incarceration of people on drug charges. More than 30,000 service members have taken their own lives in the years since Sept. 11 – four times the number of those who died on the battlefield. "I will not be told no on something that prevents human beings from killing themselves," Mr. Martinez said.

Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.

Psychedelic drugs are substances that alter perception and mood and affect a number of cognitive processes. The classic psychedelics include MDMA aka "ecstasy" or "molly," LSD, psilocybin or "mushrooms," ayahuasca and ibogaine. Used in conjunction with therapists, research has shown that psychedelics can help treat historically difficult-to-treat conditions by essentially "reshaping" the way "parts of the brain talk to each other," says Jennifer Mitchell, a neuroscientist. "Psychedelics allow for processing in a way that enables subjects to let go of things that had previously plagued them," she says. As Mitchell explains it, when people are young, their brains go through critical periods of learning and development that then become closed off as they age. Researchers believe that psychedelics "open those closed critical periods for just a tiny window of time," she says. "When that critical period is open again, you want to make the most of it, and make that potential change as positive as possible," she says. With psilocybin, for instance, it is believed the drug boosts connectivity in the brain and increases "neuroplastic states," which are the brain's ability to reorganize and adapt, says Dr. Stephen Ross ... who has been conducting clinical trials on psilocybin-assisted therapy for the past 16 years. MDMA-assisted therapy could be approved by the FDA for medical use as early as 2023, while other psychedelics, notably psilocybin, are waiting in the wings for their turn to be evaluated for medical purposes.

Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.

It's been a long, strange trip in the four decades since Rick Doblin, a pioneering psychedelics researcher, dropped his first hit of acid in college and decided to dedicate his life to the healing powers of mind-altering compounds. Dr. Doblin's quest to win mainstream acceptance of psychedelics took a significant leap forward ... when the journal Nature Medicine published the results of his lab's study on MDMA, the club drug popularly known as Ecstasy and Molly. The study, the first Phase 3 clinical trial conducted with psychedelic-assisted therapy, found that MDMA paired with counseling brought marked relief to patients with severe post-traumatic stress disorder. The results, coming weeks after a New England Journal of Medicine study that highlighted the benefits of treating depression with psilocybin, the psychoactive ingredient in magic mushrooms, have excited scientists, psychotherapists and entrepreneurs. They say it is only a matter of time before the Food and Drug Administration grants approval for psychoactive compounds to be used therapeutically – for MDMA as soon as 2023, followed by psilocybin a year or two later. Last year, Oregon became the first state to legalize the therapeutic use of psilocybin. Denver, Oakland, Calif., and Washington, D.C., have decriminalized the drug, and several states, including California, are mulling similar legislation. Though the drugs remain illegal under federal law, the Justice Department has so far taken a hands-off approach to enforcement.

Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.

In an important step toward medical approval, MDMA, the illegal drug popularly known as Ecstasy or Molly, was shown to bring relief to those suffering from severe post-traumatic stress disorder when paired with talk therapy. Of the 90 people who took part in the new study, which is expected to be published later this month in Nature Medicine, those who received MDMA during therapy experienced a significantly greater reduction in the severity of their symptoms compared with those who received therapy and an inactive placebo. Two months after treatment, 67 percent of participants in the MDMA group no longer qualified for a diagnosis of PTSD, compared with 32 percent in the placebo group. MDMA produced no serious adverse side effects. Some participants temporarily experienced mild symptoms like nausea and loss of appetite. Unlike traditional pharmaceuticals, MDMA does not act as a band-aid that tries to blunt symptoms of PTSD. Instead, in people with PTSD, MDMA combined with therapy seems to allow the brain to process painful memories and heal itself. Scott Ostrom, who participated in the study, had suffered from PTSD since returning home from his second deployment in Iraq in 2007. For more than a decade, he experienced debilitating nightmares. Mr. Ostrom's days were punctuated by panic attacks, and he dropped out of college. Therapy and medication did not help. But after participating in the trial, he no longer has nightmares. "Literally, I'm a different person," he said.

Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.

MDMA is the main ingredient in club drugs ecstasy or molly. But [Lori] Tipton wasn't taking pills sold on the street to get high at a party. She was trying to treat her post-traumatic stress disorder, with the help of licensed therapists. Two specially-trained psychotherapists ... sat next to Tipton as she recalled some of her deepest traumas, like discovering her mother's body after a murder-suicide. "I was able to find such empathy for myself. I realized how much I was thinking this was my fault," she says. The synthetic psychoactive chemical MDMA is emerging as a promising — if unconventional — treatment for PTSD. Scientists are testing how pharmaceutical-grade MDMA can be used in combination with psychotherapy to help patients who have a severe form of PTSD that has not responded to other treatments. It's not yet available as a treatment for PTSD outside of clinical trials, but the success of early trials has proponents hopeful that the therapy could be available to more people in coming years. They're aiming for approval by the The Food and Drug Administration, which granted breakthrough therapy status to MDMA-assisted psychotherapy in 2017. After the Phase 2 trials of MDMA-assisted treatments concluded in 2017, researchers found 54% of the patients who took MDMA had improved to the point that they no longer fit the diagnosis for PTSD (compared to 23% in the control group). A year later, the number who no longer had PTSD had risen to 68% percent.

Note: For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.

Important Note: Explore our full index to revealing excerpts of key major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.